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Abstract
Dystrophinopathies are characterized by skeletal and cardiac muscle complications
because  of  a  lack  or  shortened  DYSTROPHIN  protein.  Ventilation  assistance  and
corticosteroid treatment have positively affected life outcome but lead to an increased
incidence of cardiomyopathy. Cardiomyopathy is now the leading cause of death in
patients with dystrophinopathy. Thus, coherent guidelines for cardiac care have become
essential and need to be communicated well. Progression of cardiac complications in
patients  with  dystrophinopathy  diverges  from  standard  dilated  cardiomyopathy
development and monitoring and medical care for dystrophinopathy. This chapter
summarizes  current  guidelines  and  recommendations  for  monitoring  and  clinical
treatment of cardiac complications in patients with dystrophinopathy and provides a
thorough survey of emerging therapies focusing on cardiac outcomes.
Keywords: dystrophin, Duchenne and Becker muscular dystrophy, dilated cardiomy‐
opathy, symptomatic treatment, exon skipping, gene and cell therapy
1. Introduction
Dystrophinopathies are a group of diseases comprising Duchenne muscular dystrophy (DMD),
Becker muscular dystrophy (BMD) and X‐linked dilated cardiomyopathy (XLDCM), charac‐
terized by a shortened or absent DYSTROPHIN gene. DMD is the most prominent, with an
incidence around 1:5000 live male births [1]. BMD occurs about three times less than DMD [2],
while XLDCM is extremely rare [3].  DYSTROPHIN—part of the dystrophin‐glycoprotein
complex (Appendix 1)—is located on the X chromosome, and therefore, only males are affected.
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The main clinical feature of patients with dystrophinopathy is an early loss of ambulation
depending on the availability of DYSTROPHIN. Patients with DMD completely lack DYS‐
TROPHIN—the pathological mechanisms are discussed in Appendix 2—and are presented
with the most severe disease progression. This is indicated by a loss of ambulation around 10
years of age and consequent ventilation assistance, followed by death during the second or
third decade [4]. Conversely, patients with BMD still express a truncated form of DYSTRO‐
PHIN. Although only partially functional, this still has an effect on disease progression and
life expectancy, which are drastically prolonged [5]. Patients with XLDCM show the absence
of DYSTROPHIN in the heart, while expression in skeletal muscles is conserved. Several
hypotheses have been proposed for this peculiar genotype [3]. In patients with dystrophin‐
opathy, the routine use of corticosteroids and nocturnal ventilation support have dramatically
improved the life expectancy and its quality. Unfortunately, this brings up other complications,
as the incidence of cardiomyopathy is raising and is nearly ubiquitous in older patients with
DMD. In this perspective, monitoring and treatment of cardiac complications becomes more
and more important.
This chapter contains an overview of the current monitoring and treatment guidelines and
state‐of‐the‐art therapies for dystrophin‐deficient cardiomyopathies. The clinical features of
dystrophinopathies with an emphasis on cardiac disease progression will be discussed briefly,
followed by a description of the diagnostic process and current management strategies.
Conclusions from recent clinical trials on current symptomatic treatments will be summarized
and emerging therapies will be discussed in detail, from promising preclinical research to
ongoing clinical trials.
2. Clinical features
2.1. Duchenne and Becker muscular dystrophy
Neonate boys with DMD are rarely symptomatic, and the disease will not be recognized until
the second or third year of life. The patient may show evidence of mild muscle weakness before
the 12th month of life (i.e., poor head control after the 6th week, mild inability to sit unsup‐
ported at the 6th month). It is possible that he achieves the motor milestones of walking (12th
month) and running (2nd year) during the toddler period, but he will eventually be brought
to medical attention due to being less active than expected, as well as being prone to falling [6].
One of the earliest clinical signs of DMD is pseudohypertrophy of the gastrocnemii in the calves
caused by hypertrophy of muscle fibers combined with fat infiltration and proliferation of
collagen. The muscles have a firm and rubbery consistency, as well as being hypotonic
compared with unaffected muscles. By the age of 3–5 years, the clinical picture of DMD
gradually appears and “the patient straddles as he stands and waddles as he walks”. In order
to rise from the ground, the typical Gowers’ sign (i.e., the child first extends the arms and legs
assuming a four‐point position and then works each hand alternately up the corresponding
thigh) is present and it is fully expressed by the age of 5 or 6 years. While standing and walking,
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the patient places the feet wide apart to increase the base of support, and as a result of gluteus
medius weakness, there is waddling when walking [7].
The typical posture of a patient with DMD is lumbar lordosis and scoliosis (due to weakness
of abdominal muscles and paravertebral muscles) with hip flexion and abduction, knee flexion
and plantar flexion, as well as winging of the scapulae. Other common presentations in
toddlers include falling, troubles in running or using the stairs and developmental delays [7,
8]. As the muscular wasting progresses, the weakness will spread to the muscles of the legs
and forearms and patients may end up being confined to a wheelchair by 7 years of age, while
other patients may continue walking with increasing difficulty until 10 years of age. Death
usually occurs around the second decade of life, caused by pulmonary infections, respiratory
failure, aspiration, airway obstruction or heart failure [6].
In BMD, the weakness and hypertrophy appear in the same muscles as DMD, but the onset is
later (5–45 years; mean age: 12 years) with most patients losing ambulation in the third or
fourth decade. However, some patients may have a milder phenotype with the onset of
muscular weakness in late adulthood [6].
In both DMD and BMD groups, the median age of diagnosis of cardiac involvement is 14 years,
with all patients having cardiac problems after 18 years of age [8]. While in BMD, the cardiac
involvement can be the presenting symptom at diagnosis [9], and in patients with DMD, the
presentation at diagnosis is usually subclinical and asymptomatic. Patients often have
unspecific symptoms including fatigue, weight loss, nausea, sleep disturbance, cough,
palpitations, sweating, chest and abdominal discomfort, decreased urinary output, irritability
and concentration difficulties [8].
The physical examination may present some problems in patients with advanced muscular
dystrophy (MD) due to scoliosis, immobility or glucocorticoid‐related obesity. Tachycardia
will be present, unless treated with β‐blockers. Hypotension may be present—as a result of
DYSTROPHIN loss in both vascular smooth muscles and low oral fluid intake—causing
altered cardiac pacemaker activity, altered myocardial contractility and altered vasomotor
tone. Edema is not commonly present, even in the presence of advanced right and left cardiac
failure [9].
At auscultation the cardiac apex may be displaced as a result of scoliosis, with S3 gallop and
S4 gallop commonly heard as a result of acute congestive heart failure and left ventricular (LV)
dysfunction, respectively [9]. Moderate mitral regurgitation (due to posterior wall fibrosis and
LV thinning) and moderate tricuspid regurgitation may be present [10]. Neck venous en‐
gorgement may be seen as a result of abdominal compression caused by scoliosis [8].
As dystrophy progresses, the LV function worsens, leading to the clinical picture of dilated
cardiomyopathy (DCM), which can be complicated by arrhythmias. DCM is an enlargement
of one or both of the ventricles combined with systolic dysfunction, usually preceding signs
and symptoms of congestive heart failure. The hallmarks of DCM are decreased LV function
(decreased ejection fraction), LV dilation and mitral regurgitation. The latter manifests as
palpitations, vertigo, dizziness, syncope or sudden cardiac death. Moreover, in DMD, the
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arrhythmia occurs even in the absence of myocardial fibrosis [11]. Table 1 provides a summary
with the most important clinical characteristics for DMD, BMD and XLDCM.
DMD BMD XLDCM
Dystrophin Absent Partially functional Absent (heart only)
Incidence 1 : 3500–6000
male births
1 : 18,000–19,000 male births Very rare
Myopathy onset 3–5 years 12 years Variable
Loss of ambulation ~12 years ~27 years No loss
Life expectancy Mid to late 20s 40s Mid to late 10s
Cardiomyopathy
onset
16–18 years Variable, can precede skeletal
muscle symptoms
Variable, from mild to severe cases
Table 1. Characteristics of Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and X‐linked
dilated cardiomyopathy (XLDCM).
2.2. X-linked dilated cardiomyopathy
XLDCM is a cardio‐specific dystrophinopathy presenting with congestive heart failure (CHF)
due to DCM in 10‐ to 20‐year‐old patients, without the dystrophinopathy‐related involvement
of skeletal muscles (Table 1). Patients show a brisk and progressive heart failure and ventric‐
ular arrhythmias, with untreated patients that may die of congestive heart failure not long after
diagnosis [3].
3. Diagnosis and monitoring
Dystrophinopathy is generally underdiagnosed and definitive diagnosis can even take up to
2, 5 years from the onset of symptoms [12]. The first diagnostic test performed, when dystro‐
phinopathy is expected, is a serum creatine kinase (CK) measurement. In most cases, CK levels
are elevated, around 50–100 times in DMD, while in BMD levels are lower but still higher
compared to healthy patients [13]. A second level diagnostic test is a mutation analysis, which
reveals the specific genetic alteration and is useful to discriminate between DMD and BMD
[14]. Differences between DMD and BMD are clarified by the reading frame concept (Appendix
3) [15]. For 5% of the cases, mutation analysis is not able to diagnose for dystrophinopathy [16].
In this circumstance, a muscle biopsy is taken and the reduction or the absence of DYSTRO‐
PHIN is analyzed by tissue staining (immunohistochemistry and immunofluorescence) or
immunoblot (Western blot).
Recognizing cardiac complications in patients with dystrophinopathy is challenging, espe‐
cially because of physical inactivity and respiratory complications [8]. Hence, cardiomyopa‐
thies are underdiagnosed in these patients [17]. Clinical guidelines were created in 2010,
recommending an echocardiogram every 2 years from the moment of diagnosis of dystro‐
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phinopathy or from the age of 6 years. From 10 years of age, a yearly screening to asses LV
function is suggested [14]. Recently, it has been documented that cardiac MRI is more sensitive
and can distinguish cardiac complications in an earlier stage for patients with dystrophinop‐
athy [18]. Therefore, it is recommended to perform a cardiac MRI instead of echocardiography,
also because patients with dystrophinopathy can suffer from scoliosis, which makes diagnosis
with echocardiography more complicated. However, cardiac MRI can also be challenging for
pediatric patients because of the need for sedation, cost and lack of accessibility. Sinus
tachycardia is also known to precede any cardiac complications in patients with DMD [19].
As mentioned before, early diagnosis of cardiomyopathy onset is essential in patients with
dystrophinopathy. Hence, clinical trials are still undertaken to study whether electrocardio‐
gram (ECG), echocardiography, cardiac MRI and sera biomarkers can improve early detection
of myocardial involvement and clinical outcome (NCT02020954).
4. Clinical management
4.1. Pharmacological treatment
Early diagnosis of dystrophinopathies—before the onset of cardiac complications—gives the
opportunity to treat patients in a presymptomatic stage (Figure 1). However, for dystrophin‐
opathy there is no general agreement on the treatment of cardiomyopathy [20]. There are some
guidelines published to guide the decision‐making process; however, still a huge variability
in treatments exists between centers and clinicians [11].
Figure 1. Progression of dystrophin‐deficient cardiomyopathy and guidelines for monitoring and treatment. ACE, an‐
giotensin‐II‐converting enzyme.
Corticosteroids improve muscle performance and delay loss of ambulation and also have
beneficial effects on ventilation and scoliosis. However, this is accompanied by many side
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effects such as weight gain, delay of puberty, decrease of vertebral bone mass, increase of
vertebral fragility, cataract formation and growth‐failure [11]. Evidence exists that corticoste‐
roids also have advantageous effects on the heart of patients with DMD, several clinical trials
suggest a delayed onset of cardiomyopathy in patients with dystrophy [21]. However, these
results have to be interpreted with caution; all studies were retrospective without the objective
to treat for cardiomyopathic complications. In addition, corticosteroids treatment in X‐linked
muscular dystrophy (mdx) mice—an animal model for DMD with a stop codon in exon 23—
led to cases of heart failure, myocardial fibrosis and sarcolemmal damage [22]. Prospective
clinical trials are necessary to address the effect of corticosteroids on heart functionality.
Preclinical results in dystrophic mice and hamsters are concerning, especially given the broad
use of corticosteroids for treating dystrophinopathies, and reveal the gap in our understanding
about effects of corticosteroids on the heart [11]. In addition, the most suitable duration of
corticosteroid therapy still has to be determined.
The effect of angiotensin‐converting enzyme inhibitors (ACEIs) is more clear‐cut and proved
to postpone cardiomyopathy onset in both preclinical animal models and patients. A three‐
year treatment did not show any effect among a group of DMD patients treated with peri‐
ndopril and another placebo‐treated group. However, after 2 additional years of perindopril
treatment – in which both of these groups now received this drug ‐ a significant reduction in
LV ejection fraction was observed between the 5 year‐treated and 2 year‐treated group [23]. A
10‐year follow‐up study, observed a significantly higher survival rate in a group of DMD
patients that received a presymptomatic treatment with perindopril for 3 years [24]. Current
guidelines propose a start of ACEIs for DMD patients only after development of LV dysfunc‐
tion [14]. However, because aforementioned results demonstrated a clear beneficial effect of
presymptomatic treatment, it is now recommended to initiate treatment with ACEIs before
the onset of LV dysfunction in patients with DMD [25] (Figure 1). In case of observed intoler‐
ance against ACEIs, angiotensin‐II receptor blockers (ARBs) could be used instead, since they
have been shown to be as effective as ACEIs [26].
The use of β‐blockers as a combined therapy with ACEIs is common for heart failure treatment;
however, for dystrophinopathies, this is not well documented. One study described improve‐
ments in LV systolic function, when patients with DMD were treated with carvedilol [27].
Unfortunately, these findings were never reproduced in dystrophic mdx mice [28]. Study
outcomes for combined therapy were mixed and showed additional beneficial effects for β‐
blockers in some cases, and no additional advantageous effects in others [29]. Future clinical
trials need to evaluate whether the use of β‐blockers for dystrophinopathy as mono‐ or
combination therapy have beneficial effects. At the moment, it is recommended to initiate a
therapy with β‐blockers in patients with dystrophinopathy that have LV dysfunction [25].
Future studies will need to assess whether therapies combining corticosteroids with β‐blockers
and ACEIs could be of added benefit.
Mineralocorticoid receptor antagonists are a standard heart failure therapy due to their anti‐
fibrotic effect in DMD and ability to attenuate cardiomyopathy [30]. In a recent randomized
double‐blind clinical trial, one group of DMD patients with normal LV function were treated
with only ACEIs or ARBs and the other group additionally also received eplerenone (aldos‐
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terone inhibitor). Results showed a lower LV circumferential strain in both treated groups
compared to control, but not between treated groups [31]. This study is the only study of
mineralocorticoid-receptor antagonists on dystrophin-deficient cardiomyopathy, and al-
though it was not able to demonstrate a significant improvement, it is essential to investigate
further whether aldosterone inhibitors could be of any benefit for delaying cardiomyopathy
onset.
4.2. Nonpharmacological treatment
Heart transplantation is the only remedy for end-stage heart failure. Some cases have been
published in which patients with DMD received a successful transplantation with no signifi-
cant adverse effects [25]. Heart transplantation occurs more frequently in patients with BMD
because of the higher incidence of cardiomyopathy and is only recommended for patients who
have end-stage heart failure [25]. A deficit in surrogate organs complicates heart transplanta-
tion; therefore, left ventricular assist devices (LVADs) are an interesting substitution, demon-
strating effectiveness in DMD and BMD patients with advanced heart failure [25]. However,
possible postoperative complications, such as arrhythmias, bleeding, respiratory failure,
stroke and rehabilitation, need to be further addressed [25].
4.3. Treatments with indirect effects
Treatments that have no direct effect on the heart can also have considerable benefits on cardiac
function. For example, pain reduction lowers blood levels of catecholamines, which on its turn
generates no further stress on the heart.
Lung and heart function are known to affect each other. When lung function needs to be
assisted by noninvasive positive pressure ventilation (NIPPV)—because of breathing difficul-
ties—it also has favoring results on cardiac function. It leads to less strain on the heart and a
correspondingly reduced heart rate. Reduced lung function is also a strong negative predictor
of survival when the vital capacity hits one liter [32]. In addition, assisted ventilation increased
the mean survival of DMD patients with more than 10 years; however, patients who need
constant ventilation will not exceed 20 years of age [32].
Although corticosteroids treatment has positively affected the incidence of scoliosis, it still
occurs that thoracolumbar surgery becomes necessary to correct the spinal curvature [33]. In
this case, timing is important and certain risk factors are bound to patients with DMD that
have LV dysfunction [32]. Even when surgery is undertaken, it is not certain if scoliosis will
not develop. This could lead into feeding and swallowing problems [32]. When surgery is able
to prevent scoliosis onset, not only does it improve positioning and pulmonary function, but
it also ameliorates cardiac function [33]. It is important to note that—although spinal surgery
is performed in many neurological centers—it is not uniformly supported [11]. If patients with
dystrophinopathy undergo surgery, an appropriate use of anesthetics is essential and needs
to be assessed and monitored carefully before, during and after surgical intervention [34].
Table 2 gives an overview of all current clinical interventions available for the treatment of
dystrophin-deficient cardiomyopathy.







Corticosteroids Mid Initiation based on functional state
and pre-existing risk factors for adverse side-effects
[14]
Be aware of controversial cardiac
results in animal studies and clinical trials
[83]
ACEIs and ARBs High First-line therapy upon development
of LV dysfunction
[18]
Initiate therapy from 10 years of age or earlier [14]
β-Blockers Low Follow guidelines for adults with chronic heart failure [84]
Variable, normally initiation after ACEIs start




Low Timing not adequately addressed and
variation in clinical practice
[18]
Nonpharmacological
LVAD High Currently bridge to heart transplantation
but potential for destination therapy
High-risk factor: scoliosis, respiratory
muscle weakness and difficulties in recovery and rehabilitation
[85]




NIPPV High Main need for pulmonary care is from the
onset of ambulation loss. Decisions for respiratory care
must be taken by a care team




Mid For patients not receiving glucocorticoids: surgery
warranted when spinal curvature > 20°.
For patients receiving glucocorticoids: surgery
warranted upon further spinal curve progression.
[33]
ACEIs, angiotensin-converting enzyme inhibitor; ARBs, angiotensin II receptor blockers; LVAD, left ventricular assist
device; NIPPV, noninvasive positive pressure ventilation.
Table 2. Clinical treatments of dystrophin-deficient cardiomyopathy.
5. Emerging therapies
5.1. Utrophin upregulation
In 1972, UTROPHIN—a DYSTROPHIN homolog with a shortened rod domain but many
similar binding proteins—was discovered [35]. These resemblances started the speculation
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that UTROPHIN could partially compensate for DYSTROPHIN loss. More clarity was brought
by the creation of a DYSTROPHIN/UTROPHIN double knockout (mdx/utrn−/−) mouse model,
that showed a worsened skeletal and cardiac muscle phenotype with a drastically lower life
expectancy of only 2–3 months compared to mdx mice [36]. Several studies have been per‐
formed testing UTROPHIN upregulation in preclinical models, the most promising one
coming from a small molecule screening. SMT C1100 treatment demonstrated an increase of
UTROPHIN levels in mdx mice and improved muscle function [37]. A phase Ia and recently
also a phase Ib clinical trial were completed, concluding that no serious adverse effects were
accompanied by SMT C1100 treatment in healthy controls and pediatric DMD patients,
respectively [38]. It is important to mention that UTROPHIN will never be able to replace
symptoms of DYSTROPHIN deficiency because of its structural differences and lack of a NO
binding site (Appendix 1), presuming an incomplete surrogate effect.
5.2. Nonsense suppression
About 10–15% of patients with DMD carry a premature stop codon that abrogates translation
of DYSTROPHIN [39]. Aminoglycosides are mainly used as antibiotic agents but are also able
to cause a ribosomal read‐through—meaning it is able to ignore premature stop codons while
still detecting normal stop codons—and in this way generating a shortened, although func‐
tional DYSTROPHIN protein. Although promising, clinical results have been poor with
inconclusive or very low expressed DYSTROPHIN levels and major concerns about side effects
caused by Gentamicin and Negamicin [40]. Henceforth, PCT124 or ataluren was discovered
by another small‐molecule drug screening, showing promising results in preclinical animal
models without skipping normal stop codons [41]. In addition, ataluren was considered safe
and showed upregulation of DYSTROPHIN in certain subgroups of patients with DMD,
although nothing was mentioned about the heart [42–44]. These clinical trials confirmed the
need for further understanding and a division of patients with DMD in subgroups. Currently,
ataluren is involved in a randomized, double‐blind and placebo‐controlled phase III trial, with
the primary outcome being an improvement in the 6‐minute walking test (6MWT) after 48
weeks; however, cardiac function will not be monitored (NCT01826487). A search for more
effective read‐through compounds (RTCs) ended up with two more drugs: RTC13 and RTC14.
The highest efficiency was reached by RTC13. This compound restored DYSTROPHIN levels
the most in the skeletal muscle and the heart compared to gentamicin, PTC124 and RTC14.
Moreover, CK levels were reduced and muscle function was improved in mdx mice [45].
5.3. Exon skipping
The idea of exon skipping originated from BMD, due to the fact that these patients express a
shorter isoform of DYSTROPHIN and show a much milder phenotype [46]. Skipping the
genetic alteration of DYSTROPHIN so that an out‐of‐frame shift is turned into an in‐frame shift
would result in the expression of a truncated DYSTROPHIN isoform such as in BMD (Ap‐
pendix 2) [47]. Antisense oligonucleotides (AONs) are short, single‐stranded DNA sequences
that are complementary to a target pre‐mRNA splice site and able to skip exons by sterically
hindering splice enhancers [48]. This procedure should be able to treat 35% of patients with
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DMD by targeting one exon and even 83% when two exons are simultaneously targeted [49].
The downside is that AONs can only target one exon, for this reason research currently focuses
only on the most frequently involved exons [49].
There are currently two different types of AONs undergoing clinical trials: 2′O methyl
phosphorothioate (2′OMePS)—also called drisapersen [50]—and phosphorodiamidate
morpholino oligomers (PMO)—also known as eteplirsen [51]. Both were unable to improve
DYSTROPHIN expression in the heart [52, 53]. Recently, a high degree of DYSTROPHIN rescue
was achieved in the respiratory and cardiac muscles with tricyclo DNA oligomers in mdx mice
[54]. However, these results were accomplished by multiple injections and high doses of
administration (200 mg/kg per week).
Previous clinical trials picked up the inefficiency of systemic delivery of naked AONs [50, 51,
55]. For this reason, attention quickly converted toward the development of delivery methods
for AONs. Systems like cell‐penetrating peptides (CPPs) or encapsulation techniques such as
liposomes or nanoparticles appeared. CPPs are small peptides that are conjugated to AONs.
They facilitate the penetration through the plasma membrane and can be divided into three
groups: arginine rich, Pip (PNA/PMO internalization peptide) or phage and chimeric peptides.
Arginine‐rich CPPs associated with a PMO showed the first robust cardiac DYSTROPHIN
expression and an improved cardiac function [56, 57]. More recently, Pip6 conjugated with a
PMO also showed cardiac Dystrophin expression and functional improvement at low doses
[55] and prevented exercise‐induced cardiomyopathy after long‐term treatment [58]. Phage
peptides were less successful with the exception of a 7‐mer phage conjugated to 2′OMePS that
resulted in an enhanced uptake and exon skipping in the cardiac muscle [59].
Instead of a molecular approach with AONs conjugated to CPPs, it is also possible to deliver
small nuclear RNAs (snRNAs) or nucleases to the cardiac muscle. These effectors need to be
incorporated into the genome; recombinant adenoviral‐associated viruses (rAAVs) are the
preferred choice because of their long persistence in myonuclei. However, the disadvantage is
their relatively small cloning capacity (5 kb). In addition, to safely apply AAV therapy, all viral
genes have to be removed except for the components necessary for replication [60].
Delivery of U7snRNA by rAAV6 has shown to restore cardiac DYSTROPHIN expression, even
one year after injection higher DYSTROPHIN levels were still found [61]. The safety profile
and optimal concentrations of rAAV8 U7snRNA delivery in the forelimb of a large cohort of
GRMD dogs have been monitored carefully and concluded that this treatment is safe, since no
adverse immunologic responses were observed [62]. Recently, an observational study was
initiated, monitoring clinical and radiological changes of patients eligible for exon 53 skipping,
while testing their immunization against viral serotypes (NCT01385917).
Exon skipping with nucleases such as “clustered regularly interspaced short palindromic
repeats” (CRISPR) together with a Cas9 nuclease brought new insights and possibilities for
gene‐editing treatments. CRISPR/Cas9 is an immune protection system originating from
bacteria that is able to edit the genome by introducing a double‐strand break. Afterwards
genomic damage is repaired by one of the two possible repair mechanisms: nonhomologous
end‐joining (NHEJ) or homology‐directed repair (HDR). NHEJ was used as a technique for
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DYSTROPHIN exon skipping in mdx mice, a CRISPR/Cas9 was designed targeting exon 23,
leading into a removal of this exon by double‐strand breaks where after these two ends are
linked back together again by NHEJ [63]. Gene‐editing components were delivered by rAAV9
through different administration routes and showed in all cases improved Dystrophin
expression in the cardiac and skeletal muscle [63].
5.4. Gene therapy
Differently from exon skipping, it is also possible to incorporate DYSTROPHIN into the
genome instead of designing techniques to modulate native DYSTROPHIN. The advantage of
this therapy is that it is not patient specific, all patients can benefit from the same technique.
However, due to the enormous size of DYSTROPHIN, it is impossible to compact it entirely
into viral capsids. Because of the observation that short isoforms of only 45% of full‐length
DYSTROPHIN can lead to a very mild phenotype, mini‐ and microdystrophin were created,
leaving behind redundant parts [64, 65].
Some different rAAV types have shown huge promise in delivering mini‐ or microdystrophin
to the heart. Microdystrophin delivered by rAAV6 was able to incorporate itself in the skeletal,
cardiac and respiratory muscles of mdx mice; however, heart function did not recover, while
DYSTROPHIN was clearly expressed [66]. A subtype that has shown to be particularly efficient
in transfecting the heart is rAAV9 [67]. Systemic injection of minidystrophin encapsulated in
rAAV9 has shown widespread expression, also in the heart of the GRMD dogs [68].
While only one phase I clinical trial for minidystrophin has been executed [69] and another
one for microdystrophin is ongoing (NCT02376816), it is clear that this field is still at its starting
point. Many difficulties that need to addressed in the future are immunological responses and
the necessity of high viral titers [70]. However, novel techniques like fetal transduction [71],
chimeric vectors [72] and plasmapheresis [73] have already shown a drastic decrease in
immunologic responses in preclinical animal models. In addition, viral gene therapy struggles
with compaction size and eventually delivers smaller DYSTROPHIN constructs in compari‐
son to skipped DYSTROPHIN. Nevertheless, full‐length DYSTROPHIN was recently success‐
fully incorporated into the skeletal muscle of a mdx mouse through the usage of three vectors
carrying “intandem” sequential exonic parts of DYSTROPHIN [74].
5.5. Cell-based therapy
Cell therapy has some advantages compared to the aforementioned therapies. The idea of cell
therapy is to produce healthy cells, which express full length DYSTROPHIN that are able to
integrate into the tissue upon injection. In an optimal situation, these cells should also be able
to repopulate the progenitor populations such as the satellite cell pool in the skeletal muscle.
Many trials have been performed with adult stem cells like myoblasts, bone marrow‐derived
stem cells, CD133+ stem cells and mesoangioblasts (MABs). MABs are vessel‐associated
progenitors that are able to migrate across the vessel wall and have been shown to repopulate
the skeletal muscle of GRMD dogs upon systemic injection, resulting into a variable improve‐
ment of muscle function [75]. Treatment of mdx/utrn−/− mice with aorta‐derived MABs led into
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a delay of DCM onset and promotion of angiogenesis [76]. Recently, a completed phase I
clinical trial with MABs in patients with DMD showed no sign of DYSTROPHIN expression
after treatment [77]. Multiple reasons could explain this observation, such as the late age of the
patients and the lengthy procedure of isolation, which does not ensure that the cells are
delivered in an optimal way. However, systemic treatment with MABs has shown to be safe
and efforts are being made to start a phase II clinical trial.
Method Phase Model/patients References
Utrophin upregulation
Arginine butyrate Preclinical Mdx mice [87]
SMT C1100 I Healthy controls [38]
Read-through therapy
Aminoglycosides I, completed Patients with DMD and BMD [40]
Ataluren (PTC124) III, ongoing Patients with DMD NCT01826487
RTC13/14 Preclinical Mdx mice [45]
Exon skipping
Drisapersen (2’OMePS) III, recruiting Patients with DMD [51], NCT01803412
Eteplirsen (PMO) III, recruiting Patients with DMD [50, 88], NCT02255552
Tricyclo‐DNA Preclinical Mdx mice [54]
Cell‐penetrating peptide/AON Preclinical Mdx mice [55–58]
Phage peptide/AON Preclinical Mdx mice [59]
rAAV6/U7snRNA Preclinical GRMD [61]
rAAV9/CRISPR/cas9 Preclinical Mdx mice [63]
Gene therapy
rAAV6‐microdystrophin Preclinical Mdx mice [66]
rAAV9‐minidystrophin Preclinical GRMD [67, 89]
Cell-based therapy
Mesoangioblast Preclinical Mdx/utrn mice [76]
I, completed Patients with DMD [77]
iPSC‐derived cells Preclinical Sgcb‐null mice [78]
Mdx, X‐linked muscular dystrophy; DMD, Duchenne muscular dystrophy; BMD, Becker muscular dystrophy; RTC,
read‐through compound; AON, antisense oligonucleotide; rAAV, recombinant adenoviral‐associated viruses; CRISPR,
clustered regularly interspaced short palindromic repeats; GRMD, golden retriever muscular dystrophy; utrn,
Utrophin; iPSC, induced pluripotent stem cell; Sgcb, sarcoglycan beta.
Table 3. Preclinical treatments of MD‐associated cardiomyopathy.
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Recently, treatments with derivatives of induced pluripotent stem cells (iPSCs) are being
explored. iPSCs are basically (patient‐derived) somatic cells that are reprogrammed into
pluripotent stem cells that possess similar features as embryonic stem cells. These cells have
been differentiated into mesodermal‐like progenitors and injected directly into the skeletal and
cardiac muscles of Sgcb-null mice, a model for limb girdle muscular dystrophy with a worsened
phenotype compared to mdx mice. Data showed that these unique iPSC‐derived myogenic
progenitors are able to integrate into heart and limb muscles and functionally ameliorate both
cardiac and skeletal muscles of injected dystrophic mice [78].
Another advantage of cell therapy is the possibility of correcting patient‐derived cells and
reinjecting them, bypassing immunological responses. Novel strategies with CRISPR/Cas9 have
been developed to repair DYSTROPHIN in iPSCs, showing functional recovery upon differen‐
tiation [79]. Eventually, differentiation of iPSCs towards cardiomyocytes can also be used to set
up high‐throughput screenings for detecting novel patient‐tailored therapeutic molecules.
Nevertheless, there are still many aspects in cell‐based therapy that need to be addressed. As
of yet, there is no consensus about timing of injection, which is hypothesized to be crucial. As
for integration, many cell therapies suffer from extremely low integration efficiencies. Future
studies should focus on tracing the injected cells, to follow their trajectory and fate during
treatment [80]. Table 3 provides an overview of all the discussed preclinical therapies.
6. Conclusion
Since the utilization of ventilation support and corticosteroids treatment, cardiac complica‐
tions in dystrophinopathies have become more prominent, being responsible for 40% of
mortality in patients with DMD [11]. Cardiomyopathy development in patients with dystro‐
phinopathy is highly variable and can be asymptomatic for a long period of time. The earlier
onset of skeletal muscle symptoms and the sequential diagnosis can be used as an advantage
for cardiac treatment. At the moment, it is recommended to perform a cardiac MRI at the age
of 6 or right at the time of diagnosis, followed by two‐year check‐ups till the age of 10 where
after annual check‐ups are required. Momentarily, no consensus exists about initiation of
treatment. It is advised to start symptomatic treatment as soon as possible because of the
beneficial effects on cardiomyopathic progression. ACEIs are the preferred choice for treat‐
ment, because of their clear and advantageous effects on cardiomyopathy in patients with
dystrophinopathy. Effects of corticosteroids treatment on the heart remain distrustful and
cardiac deterioration should be monitored with care, while β‐blockers are shown to be effective
as stand‐alone therapy, but additive effects together with ACEIs are not observed. In addition,
transparent results about mineralocorticoid‐receptor antagonist treatment on patients with
dystrophinopathy are still missing. In the case of end‐stage heart failure, heart transplantation
or LVADs should be considered. While treatments with indirect effects on the heart like pain
reduction, NIPPV and thoracolumbar surgery could also be of added benefit for cardiac health.
Many emerging therapies exist that are being investigated in preclinical models and clinical
trials. These studies aim to enhance UTROPHIN expression, read through a stop codon
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mutation, skip the exon—that is holding the genetic alteration in DMD to express a shorter form
of DYSTROPHIN corresponding to BMD—or bring in shortened DYSTROPHIN variants by
viral or cell‐based therapy. Several of these therapies already made it into clinical trials with some
undergoing phase III trials. However, as skeletal muscle complications are the most prominent,
effects on the heart have not been taken up into the expected outcomes of these trials. This also
because in most preclinical treatments beneficial effects on the heart were absent. Novel
approaches were necessary to deliver constructs to the cardiac muscle and some preclinical
studies have shown DYSTROPHIN expression in the heart together with functional improve‐
ments in small and large animal models. Emerging literature is also showing that IPSC‐derived
myogenic progenitors from patients with dystrophy provide an attractive model to get new
insights on gene‐editing treatments. This novel technology offers possibilities for autologous
therapy and eventually targeting both cardiac and skeletal dystrophic muscles with a single
myogenic progenitor population. It is assumed that all these preclinical therapies will make it
into clinical studies and hopefully subsequently into dystrophinopathy therapies. However,
many issues still exist and need to be addressed such as immunogenic reactions toward the
administered cells or viruses, the need for high‐dosing regimens and bodywide delivery.
Appendix
Appendix 1: The dystrophin-glycoprotein complex
DYSTROPHIN functions as a linkage rod between the actin cytoskeleton and the cell membrane,
where it is connected to β‐DYSTROGLYCAN, which in turn associates with the extracellular
matrix via LAMININ. The SARCOGLYCAN complex is in close proximity to β‐DYSTROGLY‐
CAN and is important in signaling, which occurs through SYNTROPHIN and DYSTROBRE‐
VIN. Together these proteins are part of the dystrophin‐glycoprotein complex (DGC).
DYSTROPHIN also accommodates a neuronal nitric oxide synthase (nNOS)‐binding site.
Appendix 2: The molecular mechanisms of dystrophin deficiency
The 24 spectrin‐like repeats within DYSTROPHIN neutralizes contraction‐induced stress. The
absence of DYSTROPHIN leads into a loss of muscle structural integrity, which generates
membrane microruptures, leading to elevated CK levels in the serum and a high intracellu‐
lar Ca2+ concentration that subsequently activates calcium‐dependent proteases [81]. Because
of the lack of experimental proof, researchers have started questioning this theory. It became
evident that activation of stretch‐induced Ca2+ channels corresponds with elevated intracellu‐
lar Ca2+ levels, although the responsible channel has still to be found [82]. Repeated contraction‐
induced damage leads to a continuous muscle breakdown and regeneration, with an increased
build‐up of fatty and fibrotic tissue, followed by an eventual loss of muscle contractility.
Appendix 3: The reading-frame concept
A reading frame consists out of codons—three nucleotide‐based sequences—which translate
into a specific amino acid. A shift of the reading frame basically means that the reading frame
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is altered, for example by a deletion of nucleotides. If the genetic code is extended or shortened
by a multitude of “3 nucleotides”, the reading frame is sustained. Therefore, this is called an
“in‐frame shift” resulting in a partially functional protein, which corresponds to BMD. When
genetic alteration occurs by a multiplication of “1–2 nucleotides”, the reading‐frame shifts,
leading to post‐translational disintegration of DYSTROPHIN; hence, this is called an “out‐of‐
frame shift” and corresponds to DMD.
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